Literatura académica sobre el tema "GlucoCEST"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "GlucoCEST".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "GlucoCEST"
Jin, Tao, Hunter Mehrens, Kristy S. Hendrich y Seong-Gi Kim. "Mapping Brain Glucose Uptake with Chemical Exchange-Sensitive Spin-Lock Magnetic Resonance Imaging". Journal of Cerebral Blood Flow & Metabolism 34, n.º 8 (28 de mayo de 2014): 1402–10. http://dx.doi.org/10.1038/jcbfm.2014.97.
Texto completoBender, Benjamin, Kai Herz, Anagha Deshmane, Vivien Richter, Ghazaleh Tabatabai, Jens Schittenhelm, Marco Skardelly et al. "GLINT: GlucoCEST in neoplastic tumors at 3 T—clinical results of GlucoCEST in gliomas". Magnetic Resonance Materials in Physics, Biology and Medicine 35, n.º 1 (10 de diciembre de 2021): 77–85. http://dx.doi.org/10.1007/s10334-021-00982-5.
Texto completoKim, Mina, Afroditi Eleftheriou, Luca Ravotto, Bruno Weber, Michal Rivlin, Gil Navon, Martina Capozza et al. "What do we know about dynamic glucose-enhanced (DGE) MRI and how close is it to the clinics? Horizon 2020 GLINT consortium report". Magnetic Resonance Materials in Physics, Biology and Medicine 35, n.º 1 (15 de enero de 2022): 87–104. http://dx.doi.org/10.1007/s10334-021-00994-1.
Texto completoKim, Mina, Francisco Torrealdea, Sola Adeleke, Marilena Rega, Vincent Evans, Teresita Beeston, Katerina Soteriou et al. "Challenges in glucoCEST MR body imaging at 3 Tesla". Quantitative Imaging in Medicine and Surgery 9, n.º 10 (octubre de 2019): 1628–40. http://dx.doi.org/10.21037/qims.2019.10.05.
Texto completoNasrallah, Fatima A., Guilhem Pagès, Philip W. Kuchel, Xavier Golay y Kai-Hsiang Chuang. "Imaging Brain Deoxyglucose Uptake and Metabolism by Glucocest MRI". Journal of Cerebral Blood Flow & Metabolism 33, n.º 8 (15 de mayo de 2013): 1270–78. http://dx.doi.org/10.1038/jcbfm.2013.79.
Texto completoKentrup, Dominik, Annika Busch, Helga Pawelski, Eberhard Schlatter, Verena Hoerr y Stefan Reuter. "SP772NON-INVASIVE DETECTION OF ACUTE RENAL ALLOGRAFT REJECTION THROUGH GLUCOCEST MRI". Nephrology Dialysis Transplantation 30, suppl_3 (mayo de 2015): iii632. http://dx.doi.org/10.1093/ndt/gfv201.05.
Texto completoColgan, Niall, Matthew Donoghue, Zdzislaw Zuchora, Brendan Tuohy y Wil van der Putten. "Investigation of GlucoCEST as novel clinical MR biomarker of glucose metabolism". Physica Medica 32, n.º 7 (julio de 2016): 959. http://dx.doi.org/10.1016/j.ejmp.2016.05.048.
Texto completoXu, Xiang, Jiadi Xu, Kannie W. Y. Chan, Jing Liu, Huanling Liu, Yuguo Li, Lin Chen, Guanshu Liu y Peter C. M. van Zijl. "GlucoCEST imaging with on-resonance variable delay multiple pulse (onVDMP) MRI". Magnetic Resonance in Medicine 81, n.º 1 (29 de julio de 2018): 47–56. http://dx.doi.org/10.1002/mrm.27364.
Texto completoKentrup, Dominik, Philipp Bovenkamp, Annika Busch, Katharina Schuette-Nuetgen, Helga Pawelski, Hermann Pavenstädt, Eberhard Schlatter et al. "GlucoCEST magnetic resonance imaging in vivo may be diagnostic of acute renal allograft rejection". Kidney International 92, n.º 3 (septiembre de 2017): 757–64. http://dx.doi.org/10.1016/j.kint.2017.04.015.
Texto completoXu, Xiang, Jiadi Xu, Linda Knutsson, Jing Liu, Huanling Liu, Yuguo Li, Bachchu Lal et al. "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma". Magnetic Resonance in Medicine 81, n.º 6 (22 de febrero de 2019): 3798–807. http://dx.doi.org/10.1002/mrm.27683.
Texto completoTesis sobre el tema "GlucoCEST"
Delebarre, Thaddée. "Development of fast and robust metabolic imaging in humans at high magnetic field". Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPAST001.
Texto completoChemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST MRI) represents a powerful tool for the study of metabolism, offering superior temporal and spatial resolution as well as increased sensitivity compared to Magnetic Resonance Spectroscopy (MRS). CEST MRI enables the indirect detection of certain metabolites through the interaction between their labile protons and those of bulk water. CEST can map glucose, glutamate, creatine, which are important metabolites involved in cancers, and neurodegenerative and musculoskeletal diseases, representing therefore a promising bioimaging tool. The rapid development of high magnetic field MRI ((≥7 T) in recent decades greatly benefits CEST, opening up new applications and generating growing interest.The aim of this thesis is to develop CEST MRI in a clinical context, taking full advantage of high magnetic fields to increase the robustness and speed of CEST acquisitions. To this end, we focus on two main objectives. The first is to develop the CEST imaging method in a clinical environment, overcoming the practical limitations associated with high-field clinical MRI scanners, notably the strict constraints of Specific Absorption Rate (SAR) and RadioFrequency (RF) field heterogeneities (B1).To achieve this first objective, a parallel transmission CEST sequence was developed. Parallel transmission uses a multi-channel RF transmit antenna, which can be controlled independently to reduce B1 heterogeneity. Moreover, parallel transmission also allows optimized energy management using virtual observation points (a strategy developed in the laboratory) By making use of parallel transmission we have implemented an acquisition strategy which allowed us to produce CEST images with three times less B1 heterogeneity, and two times faster than compared to the state of the art literature reports.The second objective is to evaluate the performance of CEST, glucose, and glutamate weighted, in detecting and characterizing normal and pathological aging. A clinical study was carried out, involving young and elderly healthy volunteers as well as Alzheimer’s disease (AD) patients. The results showed that CEST can detect global variations in glutamate and glucose in the brain associated with aging. The acquisition and exploitation of data from AD patients is still in progress.In conclusion, this thesis has enabled the development of high-field CEST methods and the evaluation of their performance in the study of aging. These results open up encouraging prospects for the use of CEST as a biomarker of AD and other neurodegenerative diseases
Libros sobre el tema "GlucoCEST"
Hogg y European Society Of Pneumology. Glucocort Inflam Bronch Hyper: (Current Clinical Practice). Elsevier Science & Technology, 1985.
Buscar texto completoCapítulos de libros sobre el tema "GlucoCEST"
Torrealdea, Francisco, Marilena Rega y Xavier Golay. "Chapter 17 GlucoCEST: Imaging Glucose in Tumors". En Chemical Exchange Saturation Transfer Imaging, 399–426. Penthouse Level, Suntec Tower 3, 8 Temasek Boulevard, Singapore 038988: Pan Stanford Publishing, 2017. http://dx.doi.org/10.1201/9781315364421-18.
Texto completo